Results 21 to 30 of about 12,580 (199)

Favipiravir in Therapy of Viral Infections [PDF]

Journal of Clinical Medicine, 2021
Favipiravir (FPV) is a novel antiviral drug acting as a competitive inhibitor of RNA-dependent RNA polymerase (RdRp), preventing viral transcription and replication. FPV was approved in Japan in 2014 for therapy of influenza unresponsive to standard antiviral therapies.
Ryta Łagocka, Violetta Dziedziejko, Patrycja Kłos, Andrzej Pawlik   +3 more
openaire   +2 more sources

Novel favipiravir pattern-based learning model for automated detection of specific language impairment disorder using vowels

, 2022
Specific language impairment (SLI) is one of the most common diseases in children, and early diagnosis can help to obtain better timely therapy economically.
Barua, Prabal Datta, Fujita, Hamido, Aydemir, Emrah, Kaysi, Feyzi, Tuncer, Turker, Acharya, U. Rajendra, Acharya, U Rajendra, Palmer, Elizabeth, Dogan, Sengul, Erten, Mehmet   +9 more
core   +1 more source

A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic?

Journal of Virus Eradication, 2020
Background: Repurposing broad-spectrum antivirals is an immediate treatment opportunity for 2019 coronavirus disease (COVID-19). Favipiravir is an antiviral previously indicated for influenza and Ebola, which has shown some promise in early trials for ...
Victoria Pilkington, Toby Pepperrell, Andrew Hill   +2 more
doaj   +1 more source

Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterization, stability, in vitro cytotoxicity, and antiviral activity using real time cell analysis

Drug Delivery, 2022
Favipiravir, an RNA-dependent RNA polymerase (RdRp) inhibitor, is used to treat patients infected with influenza virus and most recently with SARS-CoV-2.
Ayca Yildiz Pekoz, Ozlem Akbal Dagistan, Hanan Fael, Meltem Culha, Aybige Erturk, Nur Sena Basarir, Gokben Sahin, Muge Serhatli, Gamze Cakirca, Saban Tekin, Leyla Semiha Sen, Mustafa Sevim, Lutfiye Mulazimoglu Durmusoglu, Berrak C. Yegen   +13 more
doaj   +1 more source

Cost-effectiveness of Favipiravir in moderately to severely ill COVID-19 patients in the real-world setting of Saudi arabian pandemic referral hospitals

Saudi Pharmaceutical Journal, 2023
Purpose: We aimed to evaluate the cost effectiveness of Favipiravir treatment versus standard of care (SC) in moderately to severely ill COVID-19 patients from the Saudi healthcare payer perspective.
Ahmad Alamer, Abdulaali R. Almutairi, Shiraz Halloush, Ahmed Al-jedai, Ahmed Alrashed, Mashael AlFaifi, Yahya Mohzari, Malak Almutairi, Fatimah AlHassar, Jude Howaidi, Wedad Almutairi, Ivo Abraham, Nimer Alkhatib   +12 more
doaj   +1 more source

Quantitative analysis of two COVID-19 antiviral agents, favipiravir and remdesivir, in spiked human plasma using spectrophotometric methods; greenness evaluation

BMC Chemistry, 2023
Favipiravir and remdesivir have been included in the COVID-19 treatment guidelines panel of several countries. The main objective of the current work is to develop the first validated green spectrophotometric methods for the determination of favipiravir ...
Afnan S. Batubara, Ahmed H. Abdelazim, Ahmed A. Almrasy, Mohammed Gamal, Sherif Ramzy   +4 more
doaj   +1 more source

A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test

International Journal of Infectious Diseases, 2021
As of October 2020, there is still no specific drug to treat COVID-19 as it rages worldwide. Favipiravir, indicated for the treatment of new and re-emerging influenza infections, has been suggested to be effective against SARS-CoV-2, although this is not
Yushi Murai, Hitoshi Kawasuji, Yusuke Takegoshi, Makito Kaneda, Kou Kimoto, Akitoshi Ueno, Yuki Miyajima, Koyomi Kawago, Yasutaka Fukui, Chika Ogami, Ippei Sakamaki, Yasuhiro Tsuji, Yoshitomo Morinaga, Yoshihiro Yamamoto   +13 more
doaj   +1 more source

Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19.

PLoS Medicine, 2022
BackgroundEarly antiviral treatment is effective for Coronavirus Disease 2019 (COVID-19) but currently available agents are expensive. Favipiravir is routinely used in many countries, but efficacy is unproven.
David M Lowe, Li-An K Brown, Kashfia Chowdhury, Stephanie Davey, Philip Yee, Felicia Ikeji, Amalia Ndoutoumou, Divya Shah, Alexander Lennon, Abhulya Rai, Akosua A Agyeman, Anna Checkley, Nicola Longley, Hakim-Moulay Dehbi, Nick Freemantle, Judith Breuer, Judith Breuer, Joseph F Standing, FLARE Investigators   +18 more
doaj   +1 more source

Determination of Favipiravir in Human Blood Plasma by HPLC-MS/MS

Разработка и регистрация лекарственных средств, 2023
Introduction. Favipiravir is one of the most well-known broad-spectrum drugs against many RNA viruses, including the severe acute respiratory syndrome virus 2 [severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)].
T. N. Komarov, P. A. Karpova, O. A. Archakova, D. S. Shchelgacheva, P. K. Karnakova, N. S. Bagaeva, K. Ya. Zaslavskaya, P. A. Bely, I. E. Shohin   +8 more
doaj   +1 more source

Favipiravir (T-705) inhibits Junín virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic fever. [PDF]

PLoS Neglected Tropical Diseases, 2013
Junín virus (JUNV), the etiologic agent of Argentine hemorrhagic fever (AHF), is classified by the NIAID and CDC as a Category A priority pathogen. Presently, antiviral therapy for AHF is limited to immune plasma, which is readily available only in the ...
Brian B Gowen, Terry L Juelich, Eric J Sefing, Trevor Brasel, Jennifer K Smith, Lihong Zhang, Bersabeh Tigabu, Terence E Hill, Tatyana Yun, Colette Pietzsch, Yousuke Furuta, Alexander N Freiberg   +11 more
doaj   +1 more source